CAR T cell - Wikipedia
In biology, chimeric antigen receptors (CARs)—also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors —are receptor proteins that have been …
CAR T-Cell Therapy: What It Is & How It Works - Cleveland Clinic
What is CAR T-cell therapy? Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy for some types of blood cancer. It works by turning your T lymphocytes (T …
Understanding CAR-T cell therapy for cancer: Mayo Clinic expert ...
Mar 19, 2025 · Chimeric antigen receptor T-cell therapy, or CAR-T cell therapy, is one type of immunotherapy. Sometimes likened to a “smart drug” or “living drug,” CAR-T cell therapy …
CAR T Cells: Engineering Immune Cells to Treat Cancer - NCI
Feb 26, 2025 · CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers CAR T-cell therapy involves genetically engineering a patient's own T cells (red) to attack cancer cells …
CAR T-cell Therapy and Its Side Effects - American Cancer Society
CAR T-cell therapy or CAR T therapy (short for chimeric antigen receptor T-cell therapy) is a type of cell-based gene therapy that alters the genes in a person’s T cells (a type of white blood …
Next-generation CAR-T cells design: leveraging tumor features for ...
Dec 19, 2025 · We then provide a comprehensive overview of the promising next-generation CAR-T designs and discuss the combinatorial approaches aimed at improving antigen …
CAR T cell therapy - Penn Medicine
Chimeric Antigen Receptor (CAR) T cell therapy is a type of cancer immunotherapy treatment that uses modified T cells to target cancer cells without harming the healthy cells nearby.
How CAR T-cell Therapy Works - UChicago Medicine
Learn about the multi-step CAR T-cell therapy process, from start to finish, view a video and download an infographic.
CAR-T cell therapy drives breakthroughs for many diseases
Oct 25, 2024 · CAR-T cell therapy uses T cells from a patient that are genetically engineered to express MHC-independent chimeric antigen receptors (CAR) to target a surface tumor antigen …
FDA Approves First CAR T-Cell Therapy for Marginal Zone …
Dec 4, 2025 · The U.S. Food and Drug Administration today approved a new indication for Breyanzi (Lisocabtagene maraleucel) as the first Chimeric Antigen Receptor (CAR) T-cell …